Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1965 1
1969 1
1970 2
1978 1
1984 1
2003 2
2005 3
2006 2
2007 1
2008 3
2009 1
2010 3
2011 2
2012 1
2013 3
2015 2
2016 2
2018 4
2019 4
2020 5
2021 6
2022 11
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
Gálvez NMS, Pacheco GA, Schultz BM, Melo-González F, Soto JA, Duarte LF, González LA, Rivera-Pérez D, Ríos M, Berrios RV, Vázquez Y, Moreno-Tapia D, Vallejos OP, Andrade CA, Hoppe-Elsholz G, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVacCL03 Study Group; González-Aramundiz JV, Johnson M, Goldblatt D, González PA, Abarca K, Bueno SM, Kalergis AM. Gálvez NMS, et al. Among authors: urzua m. Elife. 2022 Oct 13;11:e81477. doi: 10.7554/eLife.81477. Elife. 2022. PMID: 36226829 Free PMC article. Clinical Trial.
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.
Méndez C, Peñaloza HF, Schultz BM, Piña-Iturbe A, Ríos M, Moreno-Tapia D, Pereira-Sánchez P, Leighton D, Orellana C, Covarrubias C, Gálvez NMS, Soto JA, Duarte LF, Rivera-Pérez D, Vázquez Y, Cabrera A, Bustos S, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo M, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group; González-Aramundiz JV, González PA, Abarca K, Melo-González F, Bueno SM, Kalergis AM. Méndez C, et al. Among authors: urzua m. EBioMedicine. 2023 May;91:104563. doi: 10.1016/j.ebiom.2023.104563. Epub 2023 Apr 24. EBioMedicine. 2023. PMID: 37099842 Free PMC article.
Radiation Risk Assessment in Low-Income Countries.
Charles A, Desrosiers S, Segura E, Urzua M. Charles A, et al. Among authors: urzua m. Radiol Technol. 2023 Jan;94(3):223-224. Radiol Technol. 2023. PMID: 36631228 No abstract available.
Does Bacterial Elasticity Affect Adhesion to Polymer Fibers?
Tamayo L, Melo F, Caballero L, Hamm E, Díaz M, Leal MS, Guiliani N, Urzúa MD. Tamayo L, et al. Among authors: urzua md. ACS Appl Mater Interfaces. 2020 Mar 25;12(12):14507-14517. doi: 10.1021/acsami.9b21060. Epub 2020 Mar 12. ACS Appl Mater Interfaces. 2020. PMID: 32118396
Prevalence of filaggrin loss-of-function variants in Chilean population with and without atopic dermatitis.
Cárdenas GV, Iturriaga C, Hernández CD, Tejos-Bravo M, Pérez-Mateluna G, Cabalin C, Urzúa M, Venegas-Salas LF, Fraga JP, Rebolledo B, Poli MC, Repetto GM, Casanello P, Castro-Rodríguez JA, Borzutzky A. Cárdenas GV, et al. Among authors: urzua m. Int J Dermatol. 2022 Mar;61(3):310-315. doi: 10.1111/ijd.15887. Epub 2021 Sep 4. Int J Dermatol. 2022. PMID: 34480753
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF, Gálvez NMS, Iturriaga C, Melo-González F, Soto JA, Schultz BM, Urzúa M, González LA, Vázquez Y, Ríos M, Berríos-Rojas RV, Rivera-Pérez D, Moreno-Tapia D, Pacheco GA, Vallejos OP, Hoppe-Elsholz G, Navarrete MS, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Bueno SM, Kalergis AM. Duarte LF, et al. Among authors: urzua m. Front Immunol. 2021 Sep 29;12:742914. doi: 10.3389/fimmu.2021.742914. eCollection 2021. Front Immunol. 2021. PMID: 34659237 Free PMC article. Clinical Trial.
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F, Soto JA, González LA, Fernández J, Duarte LF, Schultz BM, Gálvez NMS, Pacheco GA, Ríos M, Vázquez Y, Rivera-Pérez D, Moreno-Tapia D, Iturriaga C, Vallejos OP, Berríos-Rojas RV, Hoppe-Elsholz G, Urzúa M, Bruneau N, Fasce RA, Mora J, Grifoni A, Sette A, Weiskopf D, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Ramírez E, Kalergis AM, Bueno SM. Melo-González F, et al. Among authors: urzua m. Front Immunol. 2021 Nov 9;12:747830. doi: 10.3389/fimmu.2021.747830. eCollection 2021. Front Immunol. 2021. PMID: 34858404 Free PMC article. Clinical Trial.
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM, Melo-González F, Duarte LF, Gálvez NMS, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Andrade-Parra CA, Vallejos OP, Piña-Iturbe A, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group; González-Aramundiz JV, González PA, Abarca K, Kalergis AM, Bueno SM. Schultz BM, et al. Among authors: urzua m. mBio. 2022 Aug 30;13(4):e0142322. doi: 10.1128/mbio.01423-22. Epub 2022 Aug 10. mBio. 2022. PMID: 35946814 Free PMC article.
61 results